Impact of AI and Human Data Utilization on Drug Discovery
Subheading
Artificial intelligence (AI) is driving innovation in drug discovery. Recently, the rapid expansion of human genomic and transcriptomic data has created an environment where AI algorithms can analyze these datasets. As data volume and computing power grow in tandem, traditional experimentâcentric approaches are reaching their limits.
Subheading
Lexogen is a company that provides highâquality RNA sequencing solutions, and Ochre Bio operates an AIâbased bioinformatics platform. Each company brings complementary strengthsâdata generation and data analysis, respectively. This complementarity can generate significant synergy for discovering new biomarkers from human data.
Subheading
Utilizing AI can compress target identification and leadâcompound screening timelines from years to months. This markedly improves costâeffectiveness before entering clinical trials, enabling faster patient access. Ultimately, productivity across the entire therapeutic development pipeline is expected to increase.
Subheading
However, the use of human data raises privacy concerns and the risk of data bias. If AI models are not adequately validated, erroneous predictions can waste research funds. Therefore, transparent data governance and ongoing model validation are essential.
The combination of AI and human data substantially reduces the cost of identifying new drug candidates and enhances pipeline value, thereby strengthening investment appeal. Collaborative models between dataâgeneration companies and AI analytics platforms demand new specialized competencies from research staff and expand career opportunities.